What Vitaros Treats: Main Uses and Benefits

Vitaros is commonly used for managing Erectile Dysfunction (ED), a condition where symptoms relate to the inability to achieve or maintain penile rigidity sufficient for satisfactory sexual performance. The medication helps address symptom clusters that create noticeable physiological strain and interfere with daily functioning, providing relief for the core symptoms of inability to achieve erection, difficulty maintaining firmness, and associated sexual function impairment.

The medication is indicated for use within this therapeutic area. It is generally applied in conditions characterized by periods of heightened symptoms where standard oral agents have been ineffective or are medically inappropriate due to pre-existing conditions. Vitaros provides support that helps ease the overall symptom burden and assists patients in managing their symptoms, contributing to improved comfort during symptomatic periods.

The primary benefit is in assisting patients to manage symptoms related to achieving a functional erection.

Quick Fact: Therapeutic Focus

Clinical Focus	Therapeutic Use
Primary Symptom	Inadequate penile rigidity/firmness
Use Context	Applied in clinical settings that involve treatment failure
Key Benefit	Assists with maintaining functional stability
Patient Relevance	Relevant for older adults and individuals with complex health situations

Eligibility Scope

Vitaros is officially indicated for the treatment of erectile dysfunction in adult men 18 years of age and older. Use in elderly persons generally requires no dose adjustment solely based on age. It is not intended for children or men below 18 years of age.

Absolute Contraindications

Regulatory documents strictly prohibit the use of Vitaros in patients with certain conditions, classified as contraindications:

• Hypersensitivity to alprostadil or any of the cream's ingredients.
• Conditions predisposing to priapism (an erection lasting four hours or more), such as sickle cell anemia, leukemia, polycythemia, or multiple myeloma.
• Penile abnormalities, including severe anatomical deformation (e.g., curvature) or active infection/inflammation such as balanitis or urethritis.
• Systemic instability, including men for whom sexual activity is inadvisable due to unstable cardiovascular or unstable cerebrovascular conditions (e.g., recent myocardial infarction or syncope).
• Patients prone to venous thrombosis or those with a hyperviscosity syndrome.

Conditional Use and Special Populations

• Organ Function: Use is not formally studied in patients with hepatic or renal insufficiency; the dose may need to be lowered due to potential impaired metabolism.
• Combination Restriction: It must not be used in combination with other erectile dysfunction treatments, such as PDE5 inhibitors.
• Partner Exposure: A condom barrier must be used during intercourse with a pregnant woman or a woman of child-bearing potential. Use is not recommended while the partner is breastfeeding.

The regulatory interaction profile for Vitaros is primarily structured around the potential for additive pharmacodynamic effects, as formal drug interaction studies with the cream formulation were not performed. The profile explicitly advises against several combinations based on these known constraints and risks.

Category	Official Regulatory Statement
Prohibited Combinations	The co-administration of Phosphodiesterase-5 (PDE-5) inhibitors (such as sildenafil, tadalafil, or vardenafil) is not recommended. This restriction is based on the official risk that an additive increased cardiovascular effect cannot be excluded due to the inherent vasoactive properties of both agents.
Vasoactive Augmentation	Concomitant use with antihypertensive drugs or other systemic vasoactive medications carries a regulatory warning for an increased risk of hypotension (low blood pressure). This interaction is specifically noted as presenting a heightened risk in elderly patients.
Additive Hemostatic Risk	Combining Vitaros with anticoagulants or platelet aggregation inhibitors is documented to increase the likelihood of local adverse hemostatic events, such as urethral bleeding or haematuria.
Metabolic Considerations	Although formal interaction studies addressing metabolic pathways were not conducted, the regulatory label notes that patients with hepatic and/or renal insufficiency may experience altered clearance, which relates to the impaired metabolism of the active ingredient.

The interaction profile is largely defined by mandatory pharmacodynamic restrictions, focusing on preventing the co-administration of medications that could amplify the drug's vasoactive or bleeding effects. No official timing-based separation rules are documented for medicinal products, and no formal studies regarding interactions with food, alcohol, or herbal products were performed.

How Vitaros Works

The mechanism is a localized, dual-action process that modulates vascular smooth muscle tone via the Prostaglandin-cAMP pathway.

Molecular Agonism and Smooth Muscle Relaxation

The active ingredient, Alprostadil, acts as an agonist at specific Prostaglandin E receptors ( EP2/ EP4) on cavernosal tissue. This interaction activates intracellular Adenylate Cyclase, causing a rapid increase in cyclic Adenosine Monophosphate (cAMP). The high cAMP concentration acts to reduce available intracellular calcium ions ( Ca^2+), which is the key cellular event leading to the relaxation of arterial and trabecular smooth muscle.

Local Delivery and Vaso-Occlusive Cascade

Dodecyl-2-(N,N-dimethylamino)propionate hydrochloride (DDAIP) acts as a permeation enhancer, temporarily modifying the epithelial barrier to enable the facilitated local transport of Alprostadil. Once smooth muscle tension is reduced, the volume of arterial inflow rapidly increases, causing the tissue to swell. This distension mechanically compresses the veins draining the area (veno-occlusion). The resulting physiological consequence is the localized trapping of blood, which imparts volume and rigidity to the corporal tissue; however, the duration of the physiological effect is constrained by the rapid local metabolism of Alprostadil.

Instruction Map: How to use Vitaros — Administration Guidelines

This map describes the administration framework for Vitaros to outline the standard application process.

---

Administration Scope

Parameter	Detail
Route of administration	Topical application to the opening at the tip of the penis (meatus).
Dosing schedule	200 mu g or 300 mu g of alprostadil via a single-use container. The initial dose is recommended by a physician.
Timing in relation to meals (if applicable)	Not applicable; administration is time-dependent on intended activity, not meals.
Preparation requirements (if applicable)	Contents of the container are brought to room temperature before administration; urination is recommended prior to application.
Age-group administration rules	Geriatric (> 65 years): No dose adjustments are typically required. Pediatrics (< 18 years): Not intended for use.
Special procedural conditions	The patient is instructed by a medical professional on the proper technique.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Topical (Meatal).
Frequency pattern	As-needed basis, with a limit of once per 24-hour period and no more than 2-3 times per week.
Use-context constraints	Applied 5 to 30 minutes before attempting intercourse; use duration is generally not established beyond 9 months.

---

Resulting Procedural Structure

Descriptive step sequence:

• The single-use AccuDose container is brought to room temperature.
• Urination is recommended before proceeding with application.
• The entire contents of the container are applied by expelling the cream into the meatus.
• The container is discarded immediately after administration.
• The patient does not urinate immediately after application.

Connection to the overall use protocol: The instructions define an intermittent-use protocol, dictating a topical route of administration that ensures localized delivery. The protocol defines quantitative limits on frequency and dose strength to ensure administration remains within established parameters. These instructions describe the necessary preparation and post-application handling required to implement the treatment.

Research Evidence / Overview of Studies for Vitaros

The core evidence base for Vitaros in the general population of men experiencing Erectile Dysfunction (ED) is primarily derived from short-term, placebo-controlled, randomized clinical trials (RCTs). These studies were used in research exploring how functional symptoms change over defined time periods. Researchers monitored adult men with ED of various origins, including those with conditions where vascular issues were present.

Evidence for Use in Men with Comorbid Conditions and Prior Treatment Failure

Research has explored Vitaros in certain specific populations, including men with underlying conditions like diabetes, hypertension, or heart disease. Studies also included men who had previously used oral ED medications (PDE5 inhibitors) and reported unsatisfactory outcomes. Data show patterns related to measured changes in erectile function for these subgroups, suggesting research exploring short-term symptom changes in these contexts. However, the sample sizes were modest for some of these specific subgroups compared to the overall study population, meaning data for these subgroups remain limited.

Long-Term Research and Durability of Study Outcomes

To gain insight into the durability of the outcomes, researchers conducted open-label extension studies following the initial, short-term RCTs, typically ranging from six to nine months. These studies monitored physiological strain and provided some data on the sustained use of the treatment. Long-term effects are not fully established beyond the nine-month follow-up period documented in these extension trials. There is limited information for long-term outcomes regarding the sustained effects of Vitaros.

Evidence Gaps and Areas of Scientific Uncertainty

While studies contribute to the broader evidence landscape for Vitaros, several scientific uncertainties and research limitations remain. The comparative evidence is lacking for Vitaros against other common, established ED treatments, such as injection therapies or oral medications. Additionally, the follow-up durations were limited in the pivotal trials, meaning long-term effects are not fully established or well-characterized in formal regulatory evidence.

Key Studies & References

1. Public Assessment Report Scientific discussion Vitaros 200 micrograms and 300 micrograms, cream (alprostadil) NL/H/3144/001-002 - Geneesmiddeleninformatiebank (Dutch Regulator)

Common questions about Vitaros (FAQ)

Q: What is Vitaros?

Vitaros is a prescription-only, topical cream (applied to the skin) used to treat erectile dysfunction (ED) in men 18 years of age and older. ED is defined as the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

---

Q: How does Vitaros work?

Vitaros contains the active ingredient alprostadil. Alprostadil is a substance that naturally occurs in the body and belongs to a group of compounds called prostaglandins. When applied to the tip of the penis, it helps relax the smooth muscles and widen the blood vessels within the penis. This action increases blood flow into the erectile tissues, which helps achieve and maintain an erection when you are sexually stimulated. The cream also contains a permeation enhancer, DDAIP (dodecyl-2-N,N-dimethylamino propionate hydrochloride), to help the alprostadil absorb through the skin.

---

Q: How quickly does Vitaros work, and how long does it last?

Vitaros typically begins to work within 5 to 30 minutes after application. The effect usually lasts for approximately one to two hours. The actual duration may vary from person to person.

---

Q: What is the maximum number of times I can use Vitaros?

You should not use Vitaros more than once within a 24-hour period. The maximum recommended frequency is two to three times per week.

---

Q: Can I use Vitaros with other erectile dysfunction treatments?

You should not use Vitaros at the same time as oral ED tablets (like sildenafil, tadalafil, vardenafil, or avanafil) or other locally applied or injectable ED treatments that also contain alprostadil. Combining these treatments can significantly increase the risk of serious side effects, such as a prolonged erection (priapism).

---

Q: What are the common side effects of Vitaros?

The most common side effects are generally localized to the application site and are usually mild or moderate and temporary. They may include:

• Aching, burning, or pain in the penis
• Tingling or throbbing sensation
• Redness (erythema) or rash
• Genital itching
• Swelling (oedema) or inflammation of the head of the penis (balanitis)

Some sexual partners may also report mild side effects, such as vaginal burning or itching.

---

Q: What should I do if my erection lasts too long?

An erection that lasts for four hours or longer is known as priapism and is a medical emergency that requires immediate attention to prevent permanent damage to the penis. If your erection persists for this duration, you must seek emergency medical assistance right away.

---

Q: Does Vitaros protect against sexually transmitted infections (STIs)?

No, Vitaros does not offer any protection against sexually transmitted infections, including HIV. Condoms must be used to prevent the spread of STIs.

Storage and Disposal of Vitaros (alprostadil) Cream

Vitaros must be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F), and it is mandatory not to freeze the product. The cream must be kept in its original sachet to protect it from light. All medicine must be kept out of the sight and reach of children.

Stability and Handling

Unopened sachets may be stored outside of the refrigerator for a maximum of three days at a temperature below 25°C (77°F). If the product is not used within this three-day period, it must be discarded. Each AccuDose container is for single use only, and any unused portion remaining after application must be immediately discarded.

Disposal

Disposal of unused medicinal product, including used AccuDose containers, should be done in accordance with local requirements. Official guidance advises placing the capped, used container back into the sachet and disposing of it in household rubbish.